Selecting immuno-oncology-based drug combinations - what should we be considering?

Expert Review of Clinical Pharmacology
Lucia FestinoPaolo A Ascierto

Abstract

Checkpoint inhibitor immunotherapy has revolutionized the treatment of many advanced stage cancers. Preexisting immunity is necessary for a response to these agents, which are most effective in inflamed tumors since they principally act by reinforcing preexisting antitumor T-cell responses. An important goal of therapy is to convert the tumor environment from non-inflamed to inflamed in order to facilitate subsequent response to checkpoint inhibitors. Clinical trials are underway to identify checkpoint inhibitor-based combination approaches, which may help to achieve this goal. Areas covered: Anti-PD-1 agents are being assessed in combination with different treatments (e.g. TLR9 agonists, oncolytic peptides, oncolytic vaccines, LAG-3, HDAC inhibitors, GITR, recombinant human interleukin-2) with promising results. PD-1 agents are also being assessed in combination with other locoregional or systemic treatment modalities, including ECT, radiotherapy, chemotherapy, and targeted therapy, with promising results being achieved. Expert commentary: Emerging approaches based on combinations with anti-PD-1 agents seem to offer increased efficacy compared to anti-PD-1 monotherapy. Such combinations also appear to be well tolerated, with s...Continue Reading

References

Jan 1, 1977·International Journal of Radiation Oncology, Biology, Physics·J AntoniadesD A Lightfoot
Oct 1, 1975·The British Journal of Radiology·D P Kingsley
Feb 18, 2004·International Journal of Radiation Oncology, Biology, Physics·Sandra DemariaSilvia C Formenti
Jul 16, 2004·The Journal of Clinical Investigation·David H MunnAndrew L Mellor
Sep 27, 2007·Journal of the National Cancer Institute·Olivier TrédanIan F Tannock
Apr 9, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Edward L Schwartz
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Aug 13, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Krithika N KodumudiJulie Y Djeu
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Dec 8, 2011·Cancer Immunology, Immunotherapy : CII·Rui-Ru JiVafa Shahabi
Dec 14, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James S WilmottRichard A Scolyer
Mar 9, 2012·The New England Journal of Medicine·Michael A PostowJedd D Wolchok
May 9, 2012·International Journal of Radiation Oncology, Biology, Physics·Emily F StamellIsaac Brownell
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jan 12, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dennie T FrederickJennifer A Wargo
Jun 19, 2013·Proceedings of the National Academy of Sciences of the United States of America·Sherene LoiJohn Stagg
Aug 16, 2013·Nature·Ludmil B AlexandrovMichael R Stratton
Feb 4, 2014·Cytokine & Growth Factor Reviews·Derek L Clouthier, Tania H Watts
Apr 9, 2014·Cancer Immunology, Immunotherapy : CII·George C PrendergastAlexander J Muller
Apr 26, 2014·Cancer Immunology Research·E Antonio Chiocca, Samuel D Rabkin
May 20, 2014·Cancer Immunology Research·F Stephen HodiDavid McDermott
Jun 1, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stanleyson V HatoW Joost Lesterhuis
Sep 11, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andreas R de BiasiPrasad S Adusumilli
Oct 29, 2014·Annals of Surgical Oncology·John F ThompsonEric A Wachter
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Dec 8, 2014·Seminars in Radiation Oncology·Karsten A PilonesSandra Demaria
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antoni Ribas, Keith T Flaherty
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk SchadendorfJedd D Wolchok
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Mar 26, 2016·Trends in Cancer·Luca AntonioliGyörgy Haskó
May 11, 2016·Genome Biology·Bernadett SzikrisztDávid Szüts
Jun 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dawn L HershmanJoseph Unger
Oct 9, 2016·The New England Journal of Medicine·Alexander M M EggermontAlessandro Testori
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Feb 6, 2017·Viral Immunology·Cecilia Martínez-CamposVicente Madrid-Marina

❮ Previous
Next ❯

Citations

Feb 6, 2020·Expert Opinion on Therapeutic Patents·Chunlong ZhaoYingjie Zhang
Aug 1, 2019·Expert Review of Clinical Pharmacology·Regina KrattingerReinhard Dummer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Expert Opinion on Biological Therapy
Antonio Maria GrimaldiPaolo A Ascierto
Current Opinion in Urology
Farhad FakhrejahaniAndrea B Apolo
Therapeutic Advances in Medical Oncology
Douglas B JohnsonJeffrey A Sosman
© 2022 Meta ULC. All rights reserved